文献速递治疗药物监测与药物基因组学特殊人群用药

新加坡多族裔人群药物基因组相关处方的流行率研究

Prevalence of pharmacogenomically implicated prescriptions in multi-ethnic populations in Singapore.
PubMed 文献 · Br J Clin Pharmacol · 2026-09-14

该研究基于新加坡国立大学医院2014至2021年电子健康记录,筛选CPIC A级或A/B级药物基因组相关药物处方,结合9051名新加坡人全基因组测序数据,估计先发药物基因组检测可修改处方的患者比例。结果显示每年38.1%至43.0%患者至少接受一种此类药物,估计18.4%患者处方可因先发检测而调整。

要点

  • 每年38.1%至43.0%患者接受至少一种CPIC A或A/B级药物基因组相关药物。
  • 最常处方药物为奥美拉唑、他汀类和曲马多,主要相关基因为CYP2C19、CYP2D6和SLCO1B1。
  • 基于变异频率估计18.4%患者处方可因先发药物基因组检测而修改。

核心结论

  • 药物基因组相关药物处方在新加坡常见,尤其在老年人群中普遍。
  • 先发药物基因组检测可能使18.4%患者的处方得到修改。

研究设计与样本

  • 研究获取新加坡国立大学医院2014至2021年电子健康记录,筛选CPIC A级或A/B级药物基因组相关药物处方。
  • 结合9051名新加坡人全基因组测序已发表数据,在人群水平估计先发药物基因组检测可修改处方的患者比例。

主要发现

  • 2014至2021年共1 157 359名独特患者就诊,每年38.1%至43.0%有处方的患者至少接受一种药物基因组相关药物,随处方年份、性别或种族/族裔变化极小。
  • 最常处方的药物基因组相关药物为奥美拉唑、他汀类和曲马多,最相关药物基因组为CYP2C19、CYP2D6和SLCO1B1。
  • 药物基因组相关药物暴露随年龄增加,且因性别显著不同,男性比女性更早被处方这些药物;印度裔和马来裔比华裔更早被处方。
  • 基于新加坡人药物基因组变异频率,估计18.4%患者可因先发药物基因组检测而修改处方。

关键数值与推荐

  • 药物基因组相关药物定义为CPIC A级或A/B级药物。
  • 每年38.1%至43.0%有处方的患者至少接受一种药物基因组相关药物。
  • 估计18.4%患者可因先发药物基因组检测而修改处方。

临床怎么用

  • 临床可关注奥美拉唑、他汀类和曲马多等高频药物基因组相关药物的先发检测。
  • 老年人群及男性、印度裔和马来裔人群可能更早暴露于药物基因组相关药物,需关注检测时机。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To assess the potential impact of implementing pre-emptive pharmacogenomic (PGx) testing in Singapore, focusing on prevalence and genetic actionability of PGx prescriptions. METHODS: Electronic Health Records from 2014 to 2021 were obtained from the National University Hospital (NUH), a tertiary medical centre serving approximately 6% of Singapore's population, which were filtered for pharmacogenomically implicated medicines (CPIC Level A or A/B), defined as PGx medications. Coupling this with published data of whole-genome sequencing of 9051 Singaporeans, we estimated the proportion of patients whose prescriptions might have been modified based on pre-emptive PGx at population level. RESULTS: From 2014 to 2021, a total of 1 157 359 unique patients were seen at NUH, with 38.1% to 43.0% of patients with prescriptions receiving at least one PGx medication annually, exhibiting minimal variance over year of prescription, sex or race/ethnicity. The most frequently prescribed PGx medications were omeprazole, statins and tramadol, while the most implicated pharmacogenes were CYP2C19, CYP2D6 and SLCO1B1. The age-dependent increase in PGx medication exposure varied significantly by sex, with males prescribed these medications earlier in life than females. Similarly, Indians and Malays were more likely to be prescribed these medicines at a younger age than Chinese. Based on frequency of PGx variants in Singaporeans, we estimate that 18.4% of patients could have their prescriptions modified from pre-emptive PGx testing. DISCUSSION: Pharmacogenomically implicated medication prescriptions are common in Singapore and are particularly prevalent in elderly populations. Strategic investments in infrastructure and policy development will be pivotal to the successful integration of pre-emptive PGx into clinical practice.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Loo ZZX, Li Z, Lee SZX, et al. Prevalence of pharmacogenomically implicated prescriptions in multi-ethnic populations in Singapore. Br J Clin Pharmacol. 2026. PMID: 42740528. doi:10.1002/bcp.70815

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。